About PDS Biotechnology Corporation
https://www.pdsbiotech.comPDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
CEO
Frank K. Bedu-Addo
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-03-18 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:2.24M
Value:$2.11M
VANGUARD GROUP INC
Shares:1.9M
Value:$1.8M
BLACKROCK, INC.
Shares:517.52K
Value:$488.9K
Summary
Showing Top 3 of 62
About PDS Biotechnology Corporation
https://www.pdsbiotech.comPDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8.14M ▲ | $-9.01M ▲ | 0% | $-0.19 ▲ | $-7.86M ▼ |
| Q2-2025 | $0 | $7.62M ▼ | $-9.43M ▼ | 0% | $-0.21 | $-7.28M ▲ |
| Q1-2025 | $0 | $9.11M ▲ | $-8.49M ▼ | 0% | $-0.21 ▲ | $-8.72M ▼ |
| Q4-2024 | $0 | $7.35M ▼ | $-7.95M ▲ | 0% | $-0.22 ▲ | $-6.84M ▲ |
| Q3-2024 | $0 | $10.18M | $-10.73M | 0% | $-0.29 | $-9.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $26.2M ▼ | $34.71M ▼ | $25.25M ▲ | $9.45M ▼ |
| Q2-2025 | $31.87M ▼ | $40.48M ▼ | $24.52M ▼ | $15.96M ▼ |
| Q1-2025 | $39.98M ▼ | $47.03M ▲ | $24.67M ▼ | $22.36M ▲ |
| Q4-2024 | $41.69M ▼ | $45.36M ▼ | $26.35M ▼ | $19M ▼ |
| Q3-2024 | $49.75M | $52.45M | $30.45M | $22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.01M ▲ | $-5.92M ▲ | $0 | $241.21K ▼ | $-5.67M ▲ | $-5.92M ▲ |
| Q2-2025 | $-9.43M ▼ | $-9.1M ▼ | $0 | $995.94K ▼ | $-8.11M ▼ | $-9.1M ▼ |
| Q1-2025 | $-8.49M ▼ | $-9.03M ▼ | $0 | $7.32M ▲ | $-1.71M ▲ | $-9.03M ▼ |
| Q4-2024 | $-7.95M ▲ | $-8.23M ▼ | $0 ▲ | $172.78K ▲ | $-8.06M ▼ | $-8.23M ▼ |
| Q3-2024 | $-10.73M | $-8M | $-1 | $17.22K | $-7.98M | $-8M |
CEO
Frank K. Bedu-Addo
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-03-18 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:2.24M
Value:$2.11M
VANGUARD GROUP INC
Shares:1.9M
Value:$1.8M
BLACKROCK, INC.
Shares:517.52K
Value:$488.9K
Summary
Showing Top 3 of 62